http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 06:05:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Lantheus+Holdings+%28LNTH%29+call+put+ratio+8.2+calls+to+1+put/26821720.html <p>Lantheus Holdings (NASDAQ: LNTH) 30-day call option implied volatility is 56; compared to its 52-week range of 33 to 97. Call put ratio 8.2 calls to 1 put into Curium in talks to acquire in roughly $7B deal, Bloomberg says.</p> http://www.streetinsider.com/Options/Lantheus+Holdings+%28LNTH%29+call+put+ratio+8.2+calls+to+1+put/26821720.html Tue, 28 Jul 2026 06:05:55 -0400 LNTH http://www.streetinsider.com/Rumors/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html <p>Curium said to near ~$7B acquisition of Lantheus - Bloomberg</p> http://www.streetinsider.com/Rumors/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html Mon, 27 Jul 2026 17:32:36 -0400 LNTH http://www.streetinsider.com/Mergers+and+Acquisitions/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html <p>Curium said to near ~$7B acquisition of Lantheus - Bloomberg</p> http://www.streetinsider.com/Mergers+and+Acquisitions/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html Mon, 27 Jul 2026 17:32:36 -0400 LNTH http://www.streetinsider.com/Trader+Talk/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html <p>Curium said to near ~$7B acquisition of Lantheus - Bloomberg</p> http://www.streetinsider.com/Trader+Talk/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html Mon, 27 Jul 2026 17:32:36 -0400 LNTH http://www.streetinsider.com/Hot+M+and+A/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html <p>Curium said to near ~$7B acquisition of Lantheus - Bloomberg</p> http://www.streetinsider.com/Hot+M+and+A/Curium+said+to+near+%7E%247B+acquisition+of+Lantheus+-+Bloomberg/26820637.html Mon, 27 Jul 2026 17:32:36 -0400 LNTH http://www.streetinsider.com/Press+Releases/Lantheus+to+Host+Second+Quarter+2026+Earnings+Conference+Call+and+Webcast+on+August+6%2C+2026%2C+at+8%3A00+a.m.+Eastern+Time/26805168.html <p>BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=GZAPIkEUJk0oSKBkDOoaiwQxq-yWXQbeLT37UyDh7yvR9h86x00u6TtitZoa1z9aeCUM6kDJ90j5LLoLq6cxRq0803hh-epZuUNf0AeWOng=" rel="nofollow" target="_blank">Lantheus Holdings, Inc.</a> (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026.</p> <p>To access the conference call or webcast, participants should register online at <a href="https://www.globenewswire.com/Tracker?data=3CCrKnxSrD1eUIc6Do6QrW8ak9u0fE3-x_fL4bPU1zVpa13pQlFKNtiVfM6HJ9nJmeLAZn9QTkN4UxpJbuesZSNal04KKjiPYI_PjVuLIScBTFws5siWDGzZTOfLVGGxPuKszk6rjwrebXlO6EqoduFTkrAKoxThoIGny-XYmnfBFt1H2YKdSp1liJM0o31G_-REkgEP1r3a9jjapbtaEQ==" rel="nofollow" target="_blank">https://investor.lantheus.com/news-events/calendar-of-events</a>. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.</p> <p>A replay will be available approximately two hours after completion http://www.streetinsider.com/Press+Releases/Lantheus+to+Host+Second+Quarter+2026+Earnings+Conference+Call+and+Webcast+on+August+6%2C+2026%2C+at+8%3A00+a.m.+Eastern+Time/26805168.html Thu, 23 Jul 2026 08:30:00 -0400 LNTH http://www.streetinsider.com/Globe+Newswire/Lantheus+to+Host+Second+Quarter+2026+Earnings+Conference+Call+and+Webcast+on+August+6%2C+2026%2C+at+8%3A00+a.m.+Eastern+Time/26805168.html <p>BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=GZAPIkEUJk0oSKBkDOoaiwQxq-yWXQbeLT37UyDh7yvR9h86x00u6TtitZoa1z9aeCUM6kDJ90j5LLoLq6cxRq0803hh-epZuUNf0AeWOng=" rel="nofollow" target="_blank">Lantheus Holdings, Inc.</a> (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026.</p> <p>To access the conference call or webcast, participants should register online at <a href="https://www.globenewswire.com/Tracker?data=3CCrKnxSrD1eUIc6Do6QrW8ak9u0fE3-x_fL4bPU1zVpa13pQlFKNtiVfM6HJ9nJmeLAZn9QTkN4UxpJbuesZSNal04KKjiPYI_PjVuLIScBTFws5siWDGzZTOfLVGGxPuKszk6rjwrebXlO6EqoduFTkrAKoxThoIGny-XYmnfBFt1H2YKdSp1liJM0o31G_-REkgEP1r3a9jjapbtaEQ==" rel="nofollow" target="_blank">https://investor.lantheus.com/news-events/calendar-of-events</a>. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.</p> <p>A replay will be available approximately two hours after completion http://www.streetinsider.com/Globe+Newswire/Lantheus+to+Host+Second+Quarter+2026+Earnings+Conference+Call+and+Webcast+on+August+6%2C+2026%2C+at+8%3A00+a.m.+Eastern+Time/26805168.html Thu, 23 Jul 2026 08:30:00 -0400 LNTH http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24110+at+TD+Cowen/26786657.html TD Cowen analyst Tara Bancroft raised the price target on Lantheus Holdings (NASDAQ: LNTH) to $110.00 (from $105.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24110+at+TD+Cowen/26786657.html Mon, 20 Jul 2026 06:33:17 -0400 LNTH http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24125+at+Truist+Securities/26776584.html Truist Securities analyst Richard Newitter raised the price target on Lantheus Holdings (NASDAQ: LNTH) to $125.00 (from $115.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Lantheus+Holdings+%28LNTH%29+PT+Raised+to+%24125+at+Truist+Securities/26776584.html Thu, 16 Jul 2026 07:09:48 -0400 LNTH http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html <p>RadioMedix, Inc., a clinical-stage biotechnology company focused on targeted radiopharmaceuticals, announced the appointment of Brian A. Markison to its board of directors, effective July 1, 2026, according to a press release.</p> <p>Markison brings more than 40 years of pharmaceutical and radiopharmaceutical industry experience to the Houston-based company. He previously served as chief executive officer and director of Lantheus Holdings, Inc. (NASDAQ: LNTH), a radiopharmaceutical company.</p> <p>Earlier in his career, Markison served as chairman and CEO of RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals. He also led Fougera Pharmaceuticals Inc. as president, CEO, and board member, guiding the company through its sale http://www.streetinsider.com/Board+Changes/RadioMedix+names+former+Lantheus+CEO+to+its+board+of+directors/26773361.html Wed, 15 Jul 2026 13:13:44 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769 http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html <p>HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.</p> <p>&quot;We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth,&quot; said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. &quot;Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading http://www.streetinsider.com/Press+Releases/RadioMedix+Appoints+Brian+A.+Markison+to+Board+of+Directors/26773359.html Wed, 15 Jul 2026 13:13:00 -0400 A.02702594 A.20020822 A.27234826 A.33723470 A.50205057 LNTH O.00029553 O.00409580 O.00729413 O.02107763 O.08450941 O.57151769